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ABSTRACT Leucine aminopeptidase (LAP) is found in all kingdoms of life and cata-
lyzes the metal-dependent hydrolysis of the N-terminal amino acid residue of pep-
tide or amino acyl substrates. LAPs have been shown to participate in the N-
terminal processing of certain proteins in mammalian cells and in homologous
recombination and transcription regulation in bacteria, while in parasites, they are
involved in host cell invasion and provision of essential amino acids for growth. The
enzyme is essential for survival in Plasmodium falciparum, where its drug target po-
tential has been suggested. We report here the X-ray structures of three kinetoplas-
tid acidic LAPs (LAP-As from Trypanosoma brucei, Trypanosoma cruzi, and Leishmania
major) which were solved in the metal-free and unliganded forms, as well as in a
number of ligand complexes, providing insight into ligand binding, metal ion re-
quirements, and oligomeric state. In addition, we analyzed mutant cells defective in
LAP-A in Trypanosoma brucei, strongly suggesting that the enzyme is not required
for the growth of this parasite either in vitro or in vivo. In procyclic cells, LAP-A was
equally distributed throughout the cytoplasm, yet upon starvation, it relocalizes in
particles that concentrate in the perinuclear region. Overexpression of the enzyme
conferred a growth advantage when parasites were grown in leucine-deﬁcient me-
dium. Overall, the results suggest that in T. brucei, LAP-A may participate in protein
degradation associated with nutrient depletion.
IMPORTANCE Leucine aminopeptidases (LAPs) catalyze the hydrolysis of the N-
terminal amino acid of peptides and are considered potential drug targets. They are
involved in multiple functions ranging from host cell invasion and provision of es-
sential amino acids to site-speciﬁc homologous recombination and transcription reg-
ulation. In kinetoplastid parasites, there are at least three distinct LAPs. The availabil-
ity of the crystal structures provides important information for drug design. Here we
report the structure of the acidic LAPs from three kinetoplastids in complex with dif-
ferent inhibitors and explore their role in Trypanosoma brucei survival under various
nutrient conditions. Importantly, the acidic LAP is dispensable for growth both in
vitro and in vivo, an observation that questions its use as a speciﬁc drug target.
While LAP-A is not essential, leucine depletion and subcellular localization studies
performed under starvation conditions suggest a possible function of LAP-A in the
response to nutrient restriction.
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Neglected tropical diseases (NTDs) are a medically diverse group of infectiousdiseases mainly affecting people in the developing world. Among the NTDs are the
diseases caused by the TriTryps, unicellular parasites of the order kinetoplastida,
namely, Trypanosoma brucei, the causative agent of African sleeping sickness, Trypano-
soma cruzi, which is responsible for Chagas’ disease, and Leishmania species, which
cause leishmaniases. Taken together, they are responsible for the suffering of millions
of people.
African sleeping sickness (or human African trypanosomiasis [HAT]), is caused by
T. brucei parasites and is ultimately fatal if left untreated. Estimates by the World Health
Organization (WHO) state that approximately 20,000 current infections with 2,804
cases were recorded in 2015 (1). Additionally, T. brucei and the closely related species
Trypanosoma vivax and Trypanosoma congolense have huge impacts on agriculture,
causing a disease called nagana in cattle and other domestic and wild animals. Chagas’
disease, caused by T. cruzi parasites, infects an estimated 8 million people in Central and
South America. The leishmaniases are caused by parasites of the genus Leishmania and
include different forms of the disease, i.e., cutaneous, mucocutaneous, and visceral
leishmaniases. The WHO estimates 700,000 to 1 million new cases and 20,000 to 30,000
deaths annually (2).
Control of these diseases is difﬁcult, as the parasites have complex life cycles
involving insect vectors. Current treatments for HAT (3), Chagas’ disease (4), and
leishmaniasis (5) are highly toxic, the treatment regimens are difﬁcult to implement,
and the availability of some of them is limited. Emerging resistance and limited efﬁcacy
of available drugs emphasize the need for the development of new drugs with novel
targets.
Peptidases are central enzymes in parasite metabolism, and some were shown to be
potential drug targets in parasitic protozoa (6–8), as in the case of Plasmodium
falciparum, the causative agent of malaria. Furthermore, the aminopeptidase inhibitor
arphamenin A was shown to inhibit the growth of T. brucei subsp. brucei cells in vitro,
suggesting aminopeptidase as a potential drug target in these parasites (9).
Leucine aminopeptidases (LAPs) are found in all kingdoms of life, with many species
encoding more than one LAP. They catalyze the metal-dependent hydrolysis of the
N-terminal amino acid of peptide or amino acyl substrates (EC 3.4.11.1, EC 3.4.11.10, EC
3.4.11.5, and EC 3.4.11.23). The structures of LAPs from many different species have
been solved (10–13), and all are homologous with overall root mean square deviations
(RMSDs) between 0.27 and 0.35 Å and a sequence identity to the TriTryp LAPs of 32 to
45%. LAPs of the M17 family of aminopeptidases are bilobal proteins with a highly
conserved C-terminal domain harboring the aminopeptidase activity. They form ho-
mohexamers of approximately 330 kDa with the active sites facing a central cavity
separated from the bulk solvent but accessible through solvent channels. The amino-
peptidase mechanism of LAPs is well characterized (14), with the activity being re-
ported to be dependent on the presence of two cocatalytic zinc ions, although activity
was shown for other divalent metal ions, e.g., manganese and magnesium (15). In
contrast, the biological functions are diverse and less well understood. In bacteria, LAPs
were shown to be involved in site-speciﬁc homologous recombination and transcrip-
tion regulation (16, 17); in plants, LAPs moonlight as molecular chaperones indepen-
dently of the aminopeptidase activity (18); in mammalian cells, they are implicated in
the N-terminal processing of certain proteins (19) and have been proposed to have a
role in the determination of cell redox status (20); while in some parasites, they
participate in host cell invasion and the provision of amino acids essential for growth
(21, 22).
There are four distinct LAPs in the TriTryp genomes, which can be classiﬁed
according to their theoretical isoelectric points as acidic (LAP-A and LAP-A2), neutral
(LAP-N), and basic (LAP-B). The sequence identity among the paralogues LAP-A, LAP-N,
and LAP-B within a species is low, with the C-terminal domain and active site being
more conserved. However, inspection of the lap-A2 genes reveals what appears to be
an incomplete LAP in all three species and their genome surroundings might suggest
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a gene duplication forming a nonfunctional pseudogene. The subcellular localization of
each of the paralogues has been predicted with PSORT II (23) to be different, indicating
distinct functions. The biochemical characterization of TriTryp LAPs to date is limited;
the enzymes studied include LAP-A from T. cruzi (24) and LAP-B from L. major,
L. donovani, L. amazonensis (25), and Trypanosoma brucei, where it has recently been
shown to be required for efﬁcient kinetoplast DNA (kDNA) division (26).
This work focused on the LAP-As of L. major (LmLAP-A), T. brucei (TbLAP-A), and
T. cruzi (TcLAP-A). We report the X-ray structures of TbLAP-A in the metal-free (apo) and
unliganded (metal-containing, holo) forms and in complex with the inhibitors bestatin
and actinonin, as well as the structures of holo TcLAP-A and LmLAP-A in complex with
actinonin. In addition, we discuss the requirements of LAP-A for survival in T. brucei by
using RNA interference (RNAi), double knockout (dKO), and overexpression of the
protein in bloodstream form (BF) and procyclic form (PF) T. brucei subsp. brucei
parasites in culture. Finally, in vivo experiments with mice were carried out to investi-
gate the effect of LAP-A knockdown on parasite infectivity.
RESULTS
Expression, purification, and confirmation of the proteolytic activity of the
LAP-As. The TriTryp LAP-As were expressed in Escherichia coli and puriﬁed successfully
by afﬁnity and size exclusion chromatography (SEC). The proteolytic activities of the
puriﬁed enzymes against the ﬂuorescent substrate analogues Leu-L-leucine-(4-methyl-
7-coumarinylamide) (Leu-AMC), L-valine-7-amido-4-methylcoumarin (Val-AMC), and
L-proline-7-amido-4-methylcoumarin (Pro-AMC) were conﬁrmed by native gel zymog-
raphy (see Fig. S1 in the supplemental material). All three LAP-As were active against
Leu-AMC, while little or no activity against Val-AMC and Pro-AMC was detected. These
ﬁndings are in agreement with the expected preference for substrates containing
leucine as the N-terminal residue, as previously reported for this family of aminopep-
tidases (27).
Crystallization of the LAP-As. TbLAP-A crystals in space group P212121 with six
chains in the asymmetric unit grew under citrate-containing conditions and comprise
apo TbLAP-A with no metal ions in the active site. TbLAP-A complexes crystallized
under many different conditions, preferentially in space group P21 with 6 or 12 chains
per asymmetric unit. All attempts to cryoprotect the crystals prior to vitriﬁcation
resulted in substantial loss of diffraction quality, and only the apo TbLAP-A crystals were
successfully cryoprotected. TcLAP-A crystallized only under citrate-containing condi-
tions, resulting in crystals in space group R32 with one or both metal ions missing from
the active site. None of the cocrystallizations with ligands yielded diffracting crystals.
LmLAP-A crystallized under many different conditions, forming hexagonal plate-like
crystals, one of which, grown in the presence of actinonin, diffracted to 2.5 Å and was
in space group P321. The crystallization conditions leading to structure solutions are
summarized in Table S1.
The TriTryp LAP-A structures. The TriTryp LAP-A structures were solved by mo-
lecular replacement (MR), and the crystallographic data and statistics are summarized
in Tables S2 to S5. The structures show a close structural similarity to each other and
LAPs of other species in the Protein Data Bank (PDB). Their nearly identical core
structures have overall RMSDs for TcLAP-A and LmLAP-A toward TbLAP-A of 0.31 and
0.33 Å, respectively, with differences limited to loop regions and minor changes in the
length of secondary structure elements.
Overall and quaternary structures in the crystals. The structures of all three
LAP-As show the typical hexameric architecture of the M17 metallopeptidases (Fig. 1A),
and analysis with PISA (28) supports the hexamer being the stable oligomeric state in
solution. All of the conformational differences seen between the TriTryp LAP-As are
located at the surface of the hexamer, away from the active site or protomer-protomer
interfaces.
Like other M17 family LAP structures in the PDB, the TriTryp LAP-As have two
domains (N and C terminal) (Fig. 1B). The smaller N-terminal domain (amino acids [aa]
Properties of Trypanosomal Leucine Aminopeptidases
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2 to 197) consists of a six-stranded  sheet (1, 6, 5, 2, 4, and 3) ﬂanked by ﬁve
 helices (2 to 6). Unlike other LAPs in the PDB, TriTryp LAP-As have an  helix at the
N terminus (-1) that interacts with the neighboring protomer of the hexamer. The
N-terminal domain is connected to the C-terminal domain via a long  helix (7).
The highly conserved C-terminal domain (aa 215 to 521), nearly identical to the
structures of other LAPs in the PDB, shows a central eight-stranded  sheet (7, 8,
10, 9, 13, 17, 14, and 15) surrounded by  helices (8 to 17) and a small 
sheet (11, 12, and 16). The C-terminal domain contains the active site and forms the
core of the hexamer, arranged around a central 3-fold axis with the active sites facing
the central cavity, secluded from the surrounding bulk solvent.
In TcLAP-A, some loop regions in the N-terminal domain (between 2 and 2, 3
and 4, 5 and 5, and 6 and 6) and in the C-terminal domain (between 8 and 9
and between 10 and 11) show conformations slightly different from those in
TbLAP-A.
Structural differences in LmLAP-A compared to TbLAP-A and TcLAP-A are mostly
located in the loop regions. The secondary structure elements and their positions in
LmLAP-A are nearly identical to those in TbLAP-A, with the exceptions of 1, 3, and 4,
which are shortened, and 2, which is replaced by a loop. The N terminus of LmLAP-A
is extended and forms a loop before the start of the 1 helix. The loop regions noted
as different for TcLAP-A are extended in LmLAP-A and again adopt different confor-
mations. Additionally, the loop between 6 and 7 is extended, harboring a small 
helix, and helix 11 in the C-terminal domain is extended by one turn.
Metal coordination in the active site and apo LAP-A. The metal-coordinating
amino acid residues in the TriTryp LAP-As are conserved and identical to those in
previously reported LAP structures. The two metal binding sites were shown to have
different binding afﬁnities for the metal ions, with site 1 generally having a lower
FIG 1 Structures of the LAP-As. Protein chains are shown in a ribbon representation. (A) Hexamer of the
TbLAP-A--bestatin complex colored by chain. The six bestatin ligands and associated metals are shown as
spheres and lie on the inside of the hexamer. (B) Superposition of TbLAP-A and LmLAP-A protomers. The
TbLAP-A N-terminal helix (1) is blue, the N-terminal domain is light blue, and the C-terminal domain is
green. For LmLAP-A, 1 is red, the N-terminal domain is coral, and the C-terminal domain is lemon. The
Mn2 ions in the active sites are shown as tan spheres. This and subsequent structure images were made
in CCP4mg (63), and superpositions were carried out with SSM (64).
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afﬁnity than site 2 (15, 29). In TbLAP-A, the carboxylate oxygen atoms of D294 and E373
and the main-chain and carboxylate oxygens of D371 coordinate the metal ion in site
1 and the carboxylate oxygens of D294, E373, and D312 and the -amino group of K289
coordinate that in site 2 (Fig. 2). The corresponding residue numbers in TcLAP-A are
K288, D293, D311, D370, and E372, and those in LmLAP-A are K299, D304, D322, D389,
and E391.
The holo TbLAP-A (crystallized in the presence of leucine), TbLAP-A complexes, and
LmLAP-A structures have two metals bound in the active site; the TcLAP-A structures,
in contrast, clearly show only one metal ion in site 1 and no metal in site 2. However,
the active-site residues adopt the same conformations as if two metal ions were bound.
Most LAP-A crystals were grown in the presence of manganese ions. As LAPs are
reported to be zinc-dependent enzymes, crystals of EDTA-treated TbLAP-A were grown
in the presence of ZnCl2. Nevertheless, X-ray ﬂuorescence (XRF) scans of the resulting
crystals indicated the presence of manganese ions, suggesting that EDTA may not to be
able to efﬁciently chelate the Mn2 ions at the concentrations used. A second data
set was collected from the same crystal at a wavelength of 1.3052 Å, between the
absorption edges of manganese and zinc, and an anomalous difference Fourier syn-
thesis was calculated for the data sets at both wavelengths by using phases from the
reﬁned model (Fig. 2). The map for the 1.3052-Å wavelength data showed peaks at
around 10  for both metal sites, substantially larger than the 7  peaks for the original
data recorded with a wavelength of 0.97949 Å, clearly indicating that neither site was
occupied by zinc. The metals were therefore modeled as manganese ions.
The structures of LAP-As in their apo and holo forms and in complex with inhibitors
are practically identical. The exception is the metal-free apo TbLAP-A form, whose
active-site loop (aa 293 to 305) is disordered and in which no electron density for bound
metal ions could be detected, most likely because of the high concentration of citrate
in the crystallization buffer. Apo TcLAP-A and the other LAP-A structures show com-
pletely ordered active sites independent of metal or ligand binding.
The TbLAP-A--bestatin complex. TbLAP-A was cocrystallized with the inhibitor
bestatin. The electron density of the ligand was well deﬁned in all 12 chains in the
asymmetric unit and was modeled in the same conformation (Fig. 3A). The bestatin
conformation mimics the gem-diolate intermediate of the peptide substrate in the
process of its cleavage, and its binding in TbLAP-A is identical to that in PfLAP (PDB
code 3KR4). The coordination of bestatin is mainly facilitated through the Mn2 ions
and hydrogen bonding. The Mn2 ions coordinate the N-2 nitrogen atom and O-2 and
O-3 oxygen atoms. Additionally, N-2 is coordinated through hydrogen bonds with the
side chain oxygens of D294 and D312, as well as the main-chain oxygen of T401. The
main-chain oxygen of D371 and the side chains of K289 and D294 form hydrogen
bonds with O-2, while the side chain of K301 forms a hydrogen bond with O-3.
Furthermore, bound HCO3 forms a hydrogen bond with the O-2 atom. While hydro-
phobic residues surround the phenyl ring of bestatin, its carboxyl group forms hydro-
gen bonds with G404 and R467.
The actinonin complexes. For both the TbLAP-A and LmLAP-A complexes, the
electron density was sufﬁcient to model the ligand, albeit with less than 100% occu-
pancy. The limited resolution and quality of the data sets do not allow accurate
FIG 2 Stereo view of the metal coordination and anomalous difference density in the active site of
TbLAP-A. The amino acid residues coordinating the two Mn2 ions in the active sites are shown as
cylinders colored by atom type. The anomalous difference maps calculated from data collected on the
same crystal at 0.9795 and 1.3051 Å are shown at the 4  level in coral and blue, respectively.
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determination of the ligand’s conformation. The TbLAP-A--actinonin complex had six
molecules in the asymmetric unit, and local noncrystallography symmetry was imposed
for the protein chains. The electron density for the ligand was generally poor but
sufﬁcient to build the actinonin in all six chains. Their densities varied slightly, so that
the ligand was modeled in each chain individually, with variation in their conforma-
tions. Nevertheless, the actinonin coordination was identical in all chains and differed
only slightly from that in LmLAP-A (Fig. 3B).
Actinonin in LmLAP-A and TbLAP-A is coordinated by the Mn2 ions and hydrogen
bonds. In both structures, the two Mn2 atoms coordinate the O-2 and O-4 oxygen
atoms of the ligand. In LmLAP-A, the side chains of K299, D304, K311, and D389 form
hydrogen bonds with O-2 and O-4, and the main-chain oxygen of L420 and the
main-chain nitrogen of G422 form hydrogen bonds with N-1 and O-13, respectively.
The N-14 atom of actinonin coordinates a water molecule. The corresponding residues
in TbLAP-A are K289, D294, K301, D371, L402, and G404, and A405 forms an additional
hydrogen bond with O-27 in four of the six chains. Because of the limited data quality,
no water molecules were modeled in the TbLAP-A structure, with the exception of
those replacing the HCO3 molecule. Superposition of the active sites including the
actinonin molecules reveals the high similarity of the conformations actinonin adopts,
with the only difference being in the hydroxymethyl-pyrrolidine moiety, which forms a
FIG 3 Inhibitor binding in the active site of the LAP-As. (A) Stereo images of the active site of TbLAP-A
in complex with Mn2 and bestatin superposed on the active site of the PfLAP-bestatin complex (PDB
code 3KR4). The coordinating residues are shown as cylinders, and the ligand is shown in a ball-and-stick
representation, both colored by atom type with the C in ice blue (TbLAP-A) or gold (PfLAP-A). The metal
coordination is represented by red dashed lines, and hydrogen bonds are shown as black dashed lines.
(B) Stereo images of the active sites of TbLAP-A and LmLAP-A in complex with Mn2 and actinonin.
Amino acid residues and ligands are colored by atom type, with the C in ice blue (TbLAP-A) or gold
(LmLAP-A). In both, the proteins were ﬁrst superposed by using the SSM option in CCP4mg for residues
from the C-terminal domain (300 to 500), followed by the “match close residues” option.
Timm et al.
July/August 2017 Volume 2 Issue 4 e00226-17 msphere.asm.org 6
hydrogen bond in TbLAP-A but not in LmLAP-A, where it is bent away from the
corresponding residue (A424).
TcLAP-A in complex with citrate. TcLAP-A crystallized exclusively under citrate-
containing conditions, which led to the absence of one or both Mn2 ions from the
active site and hence no electron density for the inhibitors. The structure obtained from
cocrystallization with the inhibitor amastatin showed clear density for one partially
occupied Mn2 ion and a citrate molecule bound in the active site. There was no
electron density for amastatin in this structure, and HCO3 is replaced by SO42
(Fig. S2). The citrate ion is coordinated by the Mn2 and hydrogen bonding, with Mn2
coordinating the O-3 and O-4 atoms from citrate, K288 forming a hydrogen bond with
O-4, and K300 forming hydrogen bonds with O-3 and O-5. Atom O-7 from the citrate
forms hydrogen bonds with D311, M308, and a water molecule. Main and side chains
of R374, G373, and K288 coordinate the SO42 molecule.
Oligomeric state in solution. The LAP-As crystallized as hexamers, as reported for
other LAP structures in the PDB. To conﬁrm the hexamer as the oligomeric state in
solution, SEC-multiangle laser light scattering (SEC-MALLS) analyses of all three LAP-As
were carried out at a range of protein concentrations. The expected molecular masses
for the different oligomeric states are summarized in Table S6 and were used to
annotate the elution peaks obtained from the SEC-MALLS data allowing for an error
of 10%. An overlay of the differential refractive index traces at a protein concentration
of 1.0 mg·ml1 with annotated peaks according to the oligomeric states corresponding
to the molecular masses is shown in Fig. S3. The analysis of TcLAP-A showed the
presence of two well-separated peaks, one with a calculated molecular mass of
~320 kDa and the other with a mass of ~170 kDa, corresponding to the hexamer and
trimer, respectively. At all of the concentrations analyzed, the hexamer was the most
abundant species, while as the concentration was lowered, the proportion of trimers
increased. Unlike for TbLAP-A, the hexameric and trimeric species were separated well
on the column, which suggests a slower interconversion of the hexamer and trimeric
TcLAP-A species than in TbLAP-A. Analysis of LmLAP-A showed three distinct molecular
mass species, corresponding to the hexamer, trimer, and monomer, plus a considerable
amount of aggregation. The three species were well separated from each other and the
aggregates in the void volume. The lower the protein concentration, the greater is the
proportion of monomers. Whether the monomers are a result of instability and
subsequently result in their aggregation or if the monomeric state is physiologically
relevant remains unclear and requires further investigation.
Knockdown and knockout of LAP-A do not impair T. brucei proliferation. To
explore the potential of TbLAP-A as a drug target and assess its essentiality for T. brucei
survival, the expression of the enzyme in both BF and PF T. brucei cells was knocked
down by using an RNAi stem-loop/stuffer strategy. This created trypanosome lines that
expressed a 465-bp fragment of the TbLAP-A gene under the control of a tetracycline-
inducible promoter.
TbLAP-A gene knockdown in BF and PF parasites was monitored by Western blotting
(Fig. 4A and B, respectively), and the resulting phenotype was examined in different
media. The RNAi-mediated depletion of LAP-A approached 95 and 100% in BF and PF
parasites, respectively, and was maintained throughout the period studied. With regard
to the effect of LAP-A depletion on parasite proliferation, RNAi-depleted strains of BF
parasites cultured in HMI-9 medium showed a growth rate similar to that of controls
(Fig. 4C). When dialyzed fetal bovine serum (FBS) was used, the growth rate was slightly
diminished yet similar in both control and LAP-A-depleted cells (Fig. 4C). For PF
parasites, RNAi-mediated knockdown of the enzyme did not result in signiﬁcant growth
defects in SDM-79 medium (Fig. 4D). In addition, a LAP-A knockout strain was achieved
for PF cells. Efﬁcient elimination of enzyme expression is shown in Fig. 5A. In minimal
essential medium (MEM) containing dialyzed FBS and therefore devoid of glucose, a
growth rate reduction of ~20% was observed in both control and dKO parasites
Properties of Trypanosomal Leucine Aminopeptidases
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(Fig. 5B). In summary, LAP-A is not an essential enzyme for the in vitro growth of either
form of the T. brucei subsp. brucei parasite when it is cultured in a range of media.
Role of LAP-A in leucine starvation. LAPs cleave amino acids, preferentially
leucine, from the N terminus of proteins or peptides and are important for protein
recycling and turnover. It is reasonable to speculate that the depletion or overexpres-
sion of an aminopeptidase will have an increased effect on cell ﬁtness upon exposure
to suboptimal extracellular amino acid concentrations. In the event of LAP-A depletion,
extracellular leucine levels might be particularly important. To test the effect of leucine
FIG 4 RNAi-mediated depletion of LAP-A in PF and BF parasites. The effect of RNAi-mediated depletion of LAP-A
on BF (C) and PF (D) parasites was analyzed. Western blot analyses of LAP-A-RNAi BF (A) and LAP-A-RNAi PFs (B)
parasites at different time points are shown. In Western blot analyses, anti-TbLAP-A antibody was used at a 1:15,000
dilution; the loading control was rabbit anti-TbSMT antibody at a 1:10,000 dilution. Each lane contained 2.5 106
parasites. Cumulative growth curves of LAP-A RNAi BF T. brucei analyzed in both HMI-9 medium containing FBS or
dialyzed FBS (C) and LAP-A RNAi PF (D) are shown. dox, doxycycline.
FIG 5 Growth phenotype of LAP-A-dKO and LAP-A-OE cells in different media and effect of leucine depletion. dKO mutants were obtained with PFs
(LAP-A-dKO), and cell proliferation was assessed. (A) Western blot analysis indicating successful elimination of LAP-A expression in different cell clones. (B)
Cumulative growth curves of PF T. brucei cultured in SDM-79 containing FBS and MEM containing dialyzed FBS. (C) Cumulative growth curves of parental,
TbLAP-A-OE (LAP-myc), and LAP-A-dKO cells grown in MEM devoid of leucine. (D) Western blot analysis indicating the level of expression of LAP-A at different
time points. Cells were diluted every 48 h. For Western blot analyses, anti-TbLAP-A antibody was used at a 1:15,000 dilution; the loading control was rabbit
anti-TbSMT antibody at a 1:10,000 dilution. Each lane contained 2.5 106 parasites. (E) Cumulative growth curves of LAP-A-OE PF parasites grown in SDM-79
and glucose-free MEM. dox, doxycycline.
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limitation on the growth and cell cycle of PFs of T. brucei subsp. brucei, cultures were
grown in glucose-free MEM prepared without leucine and with dialyzed FBS to ensure
that no small peptides or undeﬁned amino acids were present. Parental and LAP-A-dKO
cells from cultures grown in MEM containing leucine (with dialyzed FBS) were trans-
ferred to MEM without leucine and incubated at culture temperature. In the absence of
leucine, both the parental and LAP-A-dKO parasites grew deﬁciently (Fig. 5C).
Additionally, to provide an insight into the function of LAP-A in trypanosomes,
overexpressing cell lines were generated and the resulting phenotype was analyzed.
Overexpression of LAP-A fused to a myc tag in both BF and PF parasites was induced
by the addition of doxycycline. LAP-A overexpression in BFs was minor (~1.2-fold) and
had no signiﬁcant effect on proliferation, while LAP-A-overexpressing (LAP-A-OE) PF
parasites showed signiﬁcantly increased levels of LAP-A (2.5- to 3-fold), as assessed by
Western blotting (Fig. 5D), yet grew at a rate similar to that of controls (Fig. 5E).
Overexpressing PFs were further grown in MEM containing dialyzed FBS to monitor
whether the presence of high levels of the enzyme confers a selective advantage under
conditions of restricted nutrients. Lower growth rates were obtained with all of the cell
lines tested compared to SDM-79, and LAP-A overexpression appeared to be slightly
detrimental under these conditions (Fig. 5E). However, when cultured in glucose-free
MEM without leucine, LAP-A-OE parasites grew at a higher rate than controls (Fig. 5C).
Subcellular localization of LAP-A in T. brucei. BFs and PFs of T. brucei were grown
to mid-log phase and ﬁxed on poly-L-lysine-coated glass slides for determination of the
intracellular localization of TbLAP-A. Mitochondria were stained with ﬂuorescent Mito-
Tracker Red, and nuclear DNA and kDNA were visualized with 4’,6-diamidino-2-
phenylindole (DAPI). TbLAP-A was detected with afﬁnity-puriﬁed rabbit anti-TbLAP-A
antiserum. Cells were imaged by confocal and wide-ﬁeld ﬂuorescence microscopy
(Fig. 6). Parasites overexpressing c-Myc-tagged LAP-A (2 days of induction) were also
analyzed with a c-Myc-speciﬁc antibody. c-Myc-tagged LAP-A exhibited a cytosolic
distribution similar to that obtained with the anti-TbLAP-A antibody in the parental cell
line. Colocalization analysis indicated a minor overlap with mitochondria (Pearson’s
coefﬁcient, 0.5  0.1; Manders’ overlap coefﬁcient, 0.27  0.07). Thus, while TbLAP-A is
mainly cytosolic, a minor level within the mitochondrion in BFs and PFs cannot be fully
excluded. The staining disappeared upon RNAi-mediated knockdown and in LAP-A-
dKO cells, validating the speciﬁcity of the polyclonal antibody and the efﬁcacy of
RNAi-mediated depletion (Fig. 6).
Effect of nutritional starvation on LAP-A subcellular localization. Under stress
conditions such as nutritional starvation, eukaryotic cells activate several mechanisms
FIG 6 TbLAP intracellular localization. (A) Immunoﬂuorescence analysis of the intracellular localization of TbLAP in parental PF and BF parasites with anti-TbLAP
primary antibody and an Alexa Fluor 488-conjugated anti-rabbit antibody. RNAi-depleted BF parasites after induction for 4 days and LAP-A-dKO PF parasites
are also shown. Additional immunoﬂuorescence studies were performed with both BF and PF parasites overexpressing TbLAP fused with a myc tag (BF and
PF LAP-myc) with an anti-myc monoclonal antibody and an Alexa Fluor 488-conjugated goat anti-mouse antibody (B). TbLAP and TbLAP-myc are green.
Mitochondria stained with MitoTracker Red CMXRos (Mit) and nuclei and kinetoplasts stained with DAPI are red and blue, respectively. Images were collected
with an Olympus IX81 microscope and deconvolved with Huygens Professional from Scientiﬁc Volume Imaging (version 3.3) and pseudocolored with Fiji
software (61). DIC, differential interference contrast.
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to recycle the cellular content, which may cause changes in the localization of the
enzymes involved in these processes. Considering the potential participation of LAP-A
in protein recycling and amino acid supply, we sought to examine the effect of
nutritional starvation on its subcellular localization and expression. T. brucei PF parasites
were starved for 60, 120, or 180 min by incubation in phosphate-buffered saline (PBS)
and then subjected to immunoﬂuorescence analysis with the anti-TbLAP-A antibody.
Under normal conditions (untreated cells), LAP-A is homogeneously spread all over the
cytoplasm (Fig. 7A and B). However, upon nutritional starvation, the enzyme progres-
sively relocalized and accumulated in speciﬁc regions, especially in the cytoplasmic
perinuclear area (Fig. 7A and B). This phenomenon was quantiﬁed by determining the
number of particles containing LAP-A in each cell while applying an automatic thresh-
old. In untreated cells, LAP was present at an average of three particles per cell, one of
which corresponds to almost the entire cytoplasm, while during starvation, the number
FIG 7 TbLAP-A intracellular localization during nutritional starvation. (A) Immunoﬂuorescence analysis of TbLAP intracellular localization in parental PFs under
normal conditions (untreated) or during 60, 120, or 180 min of nutritional starvation (starved). (B) Three-dimensional rendering of immunoﬂuorescent parasites
showing LAP-A localization during nutritional stress performed with Imaris 4.0.6 Bitplane AG. (C) Number of particles of LAP-A signal in untreated or starved
PF parasites obtained with Fiji Particle Analyzer (ImageJ 1.51d) (61) by using the automatic default threshold; the box represents the interquartile range, and
the whiskers are maximum and minimum values. (D) Shape analysis of LAP-A particles represented by the circularity factor obtained with Fiji Particle Analyzer
(ImageJ 1.51d) (61) by using the automatic default threshold. (E) Integrated density analysis of LAP-A signal in the perinuclear area obtained with Fiji Particle
Analyzer (ImageJ 1.51d) by using the manual threshold (9.1%  0.1%). (F) Detail of the perinuclear area in untreated and starved parasites. The example
threshold is also shown. The boxes represent the interquartile range, and the whiskers are maximum and minimum values. (G) Western blot analysis of PF
whole-cell extracts during nutritional starvation. U, untreated. Fold changes (FC) in LAP-A expression calculated with respect to unstarved parasites are shown.
Asterisks represent P values calculated by two-way analysis of variance with respect to untreated parasites. ****, P  0.0001; ***, P  0.0001; **, P  0.001; *,
P  0.01.
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of particles signiﬁcantly increased (Fig. 7C). The shape of the particles resulting from
LAP-A accumulation in foci during starvation was also analyzed by measuring circular-
ity, which corresponds to 1 in the case of a perfect circle and 0 in the case of an
inﬁnitely elongated polygon. LAP-A-containing particles were signiﬁcantly more circu-
lar in starved cells than in untreated cells (Fig. 7D). Finally, quantiﬁcation of the LAP-A
signal intensity in the perinuclear region showed that signiﬁcant accumulation of the
protein occurs in this area during PBS treatment (Fig. 7E and F). However, the total
expression of TbLAP-A remains almost unchanged or slightly decreases during starva-
tion (Fig. 7G). In mammalian cells, it has been reported that lysosomes and autophagic
vesicles cluster in the perinuclear area, driven by intracellular pH changes in response
to nutritional starvation. Likewise, a perinuclear localization of autophagosomes has
been observed in trypanosomatids. Thus, TbLAP-A relocalization during nutritional
starvation suggests a possible involvement of TbLAP-A in protein degradation that
occurs in response to nutrient restriction.
Importance of LAP-A in vivo. To evaluate the role of TbLAP-A in parasite survival
within the mammalian host, C57BL/6J mice were infected with the TbLAP-A RNAi and
parental strains, downregulation in vivo was induced by doxycycline administration,
and the progression of the infection was monitored. After a few days, both the parental
and TbLAP-A RNAi cell lines showed high levels of parasitemia (109 parasites ml1) in
mice that consequently resulted in death within 5 to 6 days postinfection (Fig. 8A),
indicating that TbLAP-A is not essential for parasite viability in vivo. Efﬁcient depletion
of the enzyme in vivo was monitored by Western blotting (Fig. 8B).
DISCUSSION
LAP-A as a potential drug target in T. brucei. The data obtained indicate that
LAP-A is not essential for survival and proliferation of BF and PF T. brucei subsp. brucei
parasites under the conditions tested either in vitro or in vivo. RNAi-mediated depletion
in BF parasites and both RNAi-mediated depletion and the generation of dKO mutants
in PFs support this conclusion. Whether this is the result of redundancy caused by the
presence of additional M17 LAPs, paralogues of the one investigated, requires further
research. Recent evidence obtained with other parasites also questions the essential
character of LAP-A. Thus, bestatin, a broad-spectrum metalloaminopeptidase inhibitor
(30) reported to inhibit the M17 LAP of T. cruzi (24), was not cytotoxic against T. cruzi
after treatment at 300 M for several hours (31) under conditions where multiple
dipeptides were shown to be increased, conﬁrming in situ inhibition of the LAP. In
addition, a study with Toxoplasma gondii has shown that LAP knockout has a moderate
effect on growth but does efﬁciently block development or virulence, suggesting that
it is inadequate as a drug target also in this parasite (32). Conversely, TbLAP-B has been
FIG 8 Survival proﬁle analysis of mice infected with TbLAP-A-depleted T. brucei subsp. brucei. (A)
Kaplan-Meier survival analysis of C57BL/6J mice infected with the parental BF and TbLAP-A RNAi lines in the
absence or presence of doxycycline (DOX) to induce TbLAP-A knockdown. (B) Western blot analysis of
parasites recovered from infected animals showing efﬁcient RNAi-mediated depletion of LAP-A.
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recently shown to be required for correct segregation of kDNA, with knockdown
resulting in delayed cytokinesis and growth defects (26).
The observation that LAP-A is not an essential protein in T. brucei contrasts with its
function in P. falciparum, where its drug target potential has been demonstrated (33,
34). Likewise, it does not have an important role in survival in the mammalian host since
the infectivity of RNAi-depleted parasites in mice was similar to that of controls.
Because of the profound differences in metabolism and life cycle stages among the
TriTryps, the results obtained with T. brucei subsp. brucei parasites do not allow
conclusions to be drawn about LAP-A’s potential as a drug target in the intracellular
parasites T. cruzi and L. major, where it may be involved in host cell invasion.
TbLAP-N is predicted to localize to the endoplasmic reticulum by PSORT II (23), while
TbLAP-B has been shown to localize to the kinetoplast (26) and has a function distinct
from that of LAP-A, which is cytosolic. The establishment of subcellular LAP-A as a
cytosolic enzyme may contribute to the understanding of its physiological function,
which would be distinct from the potential endoplasmic reticulum neutral aminopep-
tidase. Thus, while LAP-A would perform metabolic or housekeeping functions in the
cytosol, in the endoplasmic reticulum, it could be involved in the posttranslational
modiﬁcation of N-terminal signal peptides of speciﬁc proteins, performing a regulatory
role. In the present study, the enzyme appears to be mainly cytosolic and mostly
excluded from the nucleus, and hence, an involvement in site-speciﬁc homologous
recombination, as reported in E. coli (35, 36), also seems improbable. A similar local-
ization of LAP-B was described in immunocytochemical studies with antibodies in
L. amazonensis promastigotes, where diffuse ﬂuorescence throughout the parasite
cytosol was observed (25). While not essential for efﬁcient proliferation, LAP-A may be
involved in sensitivity to leucine and nutrient starvation. In mammalian cells, leucine
starvation has been shown to induce increased lysosome-dependent protein break-
down to replenish amino acid pools (37). In T. brucei PF cells, starvation stress induces
the presences of a functional autophagy pathway (38). PF parasites exposed to leucine
depletion grew at very low rates and entered a short stationary phase before under-
going cell death. LAP-A-OE parasites appear to exhibit consistently a growth advantage
under these conditions, which suggests a role for the enzyme in protein breakdown
and the maintenance of leucine pools. Interestingly upon nutrient starvation, the
location of LAP-A changed and concentrated in vesicles in the nuclear periphery. While
the nature of these vesicles remains to be established, we postulate that LAP-A is
recruited for speciﬁc functions related to protein and amino acid homeostasis and may
be important for the cellular response to events related to a limited nutrient supply.
Structure and oligomeric state of LAP-A and their effects on possible physio-
logical substrates. The TriTryp LAP-As form hexamers in solution and in the crystal,
and homology to other LAPs indicates that this oligomeric state is a key feature of this
family of enzymes. The active site of each protomer faces the inner cavity, sequestered
from the bulk solvent. Although access channels allow diffusion into the inner cavity
and the active sites, the accessibility seems restricted to small, unfolded substrates. This
favors LAP-A’s function as a mainly metabolic enzyme whose function is housekeeping
or trimming of the N termini of speciﬁc unfolded peptides. Nevertheless, the bacterial
M17 family LAPs PepA and PepB were shown to cleave the loosely folded protein casein
in vitro (39), indicating LAP’s potential to process larger substrates.
The physiological metal ion in the active site of LAP-A.While early studies on the
bovine lens LAP showed Zn2 to be the physiological metal ion in the active site of the
M17 family LAPs (15), the enzyme was also shown to be active with other divalent metal
ions (24, 25, 40–42). It was noted earlier (12) that Pseudomonas putida LAP produced in
E. coli has Mn2 in its active site, with the substrate speciﬁcity being inﬂuenced by the
identity of the metal in the active site (20), with sulfhydryl-containing substrates only
being accepted by Mn2-containing LAPs and not by Zn2-containing LAPs.
Within this study, the best crystals of the TriTryp LAP-As grew in the presence of
Mn2 and indeed, crystals grown under Zn2-containing conditions still retained
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Mn2 in the active site. This might indicate that Mn2 is the physiological metal
copuriﬁed with the enzyme expressed in E. coli. Given the similar estimates of
manganese and zinc ion concentrations on the order of 10 to 100 M in the cytosol,
further studies are required to conﬁrm which of these is the physiological metal in
these enzymes.
In summary, the structures of the TriTryp LAP-As were solved in the apo form and
several ligand complexes, which gives insight into ligand binding and conﬁrms the
homology to other family members. The biological data show that LAP-A is not
essential either for growth in vitro or for infectivity in mouse models, therefore
precluding its exploitation as a drug target. Protection against leucine depletion and
the behavior of the enzyme during starvation suggest a possible role in the response
to nutrient restriction.
MATERIALS AND METHODS
Cloning of LAP-A genes and protein expression in E. coli. The genes encoding the LAP-As were
ampliﬁed from genomic DNA (T. brucei Lister427, T. cruzi Sylvio X10/1, and L. major Friedlin) and cloned
into the YSBLIC3C vector by ligase-independent cloning (43). Successful cloning was conﬁrmed by
restriction endonuclease digestion and sequencing. The resulting constructs (pTbLAP-3C, pTcLAP-3C, and
pLmLAP-3C) encoded the LAP-A proteins with an N-terminal fusion to a hexahistidine tag separated from
the N terminus of the protein by the recognition site of the human rhinovirus (HRV) 3C protease.
Recombinant full-length TbLAP-A was overexpressed from the pTbLAP-3C vector into BL21(DE3) cells
grown in LB medium supplemented with 35 g·ml1 kanamycin. TcLAP-A and LmLAP-A recombinant
proteins were expressed from the pTcLAP-3C and pLmLAP-3C vectors into pLEMO(DE3) cells grown in LB
medium supplemented with 35 g ml1 kanamycin and 34 g ml1 chloramphenicol. TbLAP-A expres-
sion was induced with 1 mM isopropyl--D-thiogalactopyranoside (IPTG) for 4 h at 37°C. TcLAP-A and
LmLAP-A expression was induced overnight at 20°C with 1 mM IPTG. Cells were harvested by centrifu-
gation, and the pellet was frozen at 20°C.
Purification and confirmation of peptidolytic activity. Cell pellets from each culture were
thawed on ice, resuspended in buffer A (20 mM Tris [pH 8.0], 300 mM NaCl, 30 mM imidazole, 1 mM
dithiothreitol [DTT]) containing 100 M phenylmethylsulfonyl ﬂuoride, and lysed by sonication. The
cell debris was removed by centrifugation for 30 min at 5,000  g and 4°C, and the supernatant was
loaded onto an equilibrated 5-ml HisTrap crude FF column (GE Healthcare). Protein was eluted with
an imidazole gradient of 30 to 500 mM in buffer A, and the protein-containing fractions identiﬁed
by SDS-PAGE were pooled. The LAP-As with cleavable N-terminal His tags were concentrated to
~30 ml before the addition of HRV 3C protease in an approximate ratio of 1:100 (protease-to-LAP-A
ratio). Proteolysis was monitored by SDS-PAGE and reached completion after 16 h at 4°C. Subse-
quently, the protein buffer was exchanged into buffer A with centrifuge ﬁlters (Amicon Ultra
Centrifugal Filter from Millipore or Vivaspin6 from Sartorius Stedim Biotech, 50-kDa cutoff) and
another nickel afﬁnity puriﬁcation performed as described above. The untagged LAP-A in the
ﬂowthrough fraction was concentrated to an ~1-ml total volume and injected onto a Superdex 200
16/600 column (GE Healthcare) equilibrated in SEC buffer (10 mM Tris [pH 8.0], 200 mM NaCl, 1 mM
DTT). TbLAP-A fused to a noncleavable His tag was concentrated to ~1 ml and loaded directly onto
the equilibrated Superdex 200 16/600 column after the ﬁrst nickel afﬁnity puriﬁcation step. The ﬁnal
purity was analyzed by SDS-PAGE, and the protein-containing fractions of one elution peak were
pooled and buffer exchanged into a mixture of 20 mM Tris (pH 8.0), 300 mM NaCl, and 1 mM DTT.
The LAP-As were concentrated, vitriﬁed in liquid nitrogen, and stored at 80°C.
Each of the puriﬁed LAP-As was mixed with native gel loading buffer (100 mM Tris [pH 6.8], 20%
[vol/vol] glycerol, 0.1% [wt/vol] bromophenol blue) and loaded three times onto one 5% polyacryl-
amide gel. Electrophoresis was carried out at 100 V for 2 h at 4°C to prevent denaturation of the
proteins. Afterward, the gel was washed three times for 20 min in 50 mM Tris (pH 8.0) and
subsequently cut into three pieces, with each piece containing all three LAP-As. Each gel piece was
incubated in activity assay buffer (50 mM Tris [pH 8.0], 100 mM KCl, 1 mM MnCl2) containing 7.5 M
ﬂuorescent substrate for 10 min at 37°C in the dark. The ﬂuorescent substrates tested were Leu-AMC,
Val-AMC, and Pro-AMC. After incubation, the ﬂuorescent products on the gel were detected with a
UV light imager and the gel pieces were subsequently stained with Coomassie to estimate the
amount of LAP-A loaded on each gel piece.
SEC-MALLS. Puriﬁed and frozen TbLAP-A, TcLAP-A, and LmLAP-A were thawed and diluted to
concentrations of 0.1, 0.5, 1.0, and 3.0 mg ml1, and additionally, TbLAP-A was diluted to 5 mg ml1. The
LAP-As were incubated at the respective concentrations for a minimum of 3 h at room temperature to
allow potential concentration-dependent oligomeric state changes. The samples were injected automat-
ically into a SEC-MALLS system (Wyatt Dawn HELEOS-II 18-angle light scattering detector and Wyatt
Optilab rEX refractive index monitor linked to a Shimadzu high-performance liquid chromatography
system comprising LC-20AD pump, a SIL-20A Autosampler, and an SPD20A UV/Vis detector) with a
Superdex 200 10/300 size exclusion column (GE Healthcare) and a running buffer containing 10 mM Tris
(pH 8.0), 200 mM NaCl, and 1 mM DTT. The data were analyzed with the ASTRA software (version
5.3.4.14), and the molecular mass of each sample was calculated.
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Crystallization, data collection, and structure determination. Prior to crystallization, the LAP-As
were thawed at room temperature and preincubated with the desired metal salts for 2 h and subse-
quently with ligand for another 2 h on ice. Precipitated protein was removed by centrifugation, and the
ﬁnal protein concentration was determined. All crystals were grown at 20°C. Crystals were optimized by
sitting- and hanging-drop vapor diffusion with a drop size of 1 l of protein plus 1 l of well solution.
For LmLAP-A, the additive screen (Hampton Research) was used to identify a compound that enhanced
the diffraction of the crystals. The conditions leading to LAP-A crystals that allowed structure solution and
the ligands bound in the active sites of these structures are listed in Table S1. The crystal of apo TbLAP-A
was cryoprotected in well solution containing 20% (vol/vol) glycerol prior to vitriﬁcation. The other LAP-A
crystals were not cryoprotected.
All computations were carried out with programs of the CCP4 suite (44), unless stated otherwise. The
data were processed with MOSFLM (45) and AIMLESS (46). Crystallographic data and statistics are shown
in Tables S2 to S5.
The structures were solved by MR with PHASER (47) or MOLREP (48). The highest structural homology
to TbLAP-A was predicted to be the Caenorhabditis elegans LAP by BLAST searching against entries in the
PDB, and the protomer of PDB entry 2HB6 was used in MR to generate initial phases from which the
TbLAP-A model was built. For all subsequent LAP-A structures, the ﬁrst TbLAP-A model (apo) was used
for MR. Model building was carried out with BUCCANEER (49), and manual ﬁtting of the electron density
maps and model building and ﬁtting of the ligands were carried out in Coot (50). The structures were
reﬁned with REFMAC5 (51) and validated with Coot and MolProbity (52).
Identification of metal ions in the TbLAP-A structure. The crystal grown in the presence of ZnCl2
and L-leucine used protein treated with EDTA during puriﬁcation to remove any metals, and no other
metal except ZnCl2 was added prior to crystallization. XRF scans of this crystal were collected and
analyzed with the PyMca software (53), but a speciﬁc edge scan for zinc gave no signal. X-ray diffraction
data were collected at each side of the theoretical zinc edge at wavelengths of 0.9795 and 1.3051 Å and
after data processing with Xia2 (54) and structure solution and reﬁnement as described above. The
reﬂection data from REFMAC5 (including the phases) were combined with the Friedel difference (DANO)
and the standard deviation of F2 (SIGDANO) from the unmerged data ﬁle (from Xia2) by CAD from CCP4,
and anomalous difference maps were generated with the FFT program in CCP4.
Anti-TbLAP antibody generation. Ten milligrams of pure recombinant TbLAP-A was lyophilized,
resuspended in PBS, mixed with Freund’s adjuvant (1:1 ratio), and injected into a rabbit in four
inoculations of ~400 g of protein each to obtain an anti-TbLAP polyclonal antibody. Antiserum was
extracted before the inoculation and tested for the recognition of TbLAP-A in T. brucei lysates and
puriﬁed recombinant protein. The antibody was afﬁnity puriﬁed by using pure recombinant TbLAP-A
coupled to Afﬁ-Gel 15 Gel resin (Bio-Rad) in accordance with the manufacturer’s instructions. Antibody
sensitivity and speciﬁcity were tested via Western blot analysis (Fig. S4).
Generation of LAP-A-RNAi, LAP-A-dKO, LAP-A-OE, and LAP-A-myc lines. A fragment of 465 bp
(positions 10 to 475 of the coding region) of the TbLAP-A open reading frame (ORF) sequence was
ampliﬁed by PCR from genomic DNA (T. brucei Lister427) with forward primer 5= GCGGATCCAAGCTTT
ACCCAAGGCCGAAGCAAAA 3= and reverse primer 5= GCGTTAACGGGCCCCGTGCTACAGCAGCAGCGAT 3=
containing the recognition sites (underlined) for BamHI-HindIII and HpaI-ApaI, respectively. The primers
were designed by using the sequence found in the GeneDB database (Tb427tmp.02.4440) and validated
with the TrypanoFAN-RNAit software (55). After a ﬁrst cloning into the HindIII and ApaI sites of plasmid
pGR19 (56), the fragment was cloned in the BamHI and HpaI restriction sites of the previous construct
in the antisense orientation to create a hairpin structure of the transcribed RNA. The plasmid obtained
was used to induce downregulation of TbLAP-A in T. brucei by RNAi. To obtain stable TbLAP-A depletion,
two replacement cassettes for the dKOs of the gene were generated. A 538-bp fragment of the 5=
untranslated region (UTR) upstream of the TbLAP-A gene (positions 61 to 599) and a 467-bp fragment of
the 3= UTR downstream of the TbLAP-A gene (positions 7 to 475) were ampliﬁed from genomic DNA with
5= UTR forward primer 5= CGCGGCCGCGGGAGGCGGTAATGACAAGTC 3= (NotI restriction site underlined), 5=
UTR reverse primer 5= GCCTCGAGGCTTCAGGTCCCCTTATGCAC 3= (Xho1 restriction site underlined), 3= UTR
forward primer 5= GCAGGCCTGGCGTGCAAGTATCGGTTCCC 3= (Stu1 restriction site underlined), and 3= UTR
reverse primer 5= GGCTAGCGCGGCCGCGTAGCGAGTAAACGAGTAAACTCA 3= (Nhe1 and Not1 sites under-
lined). The 5= UTR fragment was cloned into the pHD887 vector (57) with the XhoI and NotI endonucleases.
Subsequently, the 3= UTR fragment was cloned into the resulting vector from the previous step with StuI and
NheI. The resulting vector (pHD887B/UTRs) contained the blasticidin S transferase resistance gene and was
used to transform parental T. brucei parasites for the suppression of the ﬁrst allele. To remove the second
TbLAP-A allele from the genome, the hygromycin phosphotransferase (HYG) selectable marker was subcloned
into pHD887B/UTRs. The resulting vector, pHD887H/UTRs, was used to transfect the positive single-knockouts
clones. In addition, the TbLAP-A gene (Tb427tmp.02.4440) ORF was ampliﬁed by PCR and cloned into vectors
pGRV23b and pGRV33 (57) with ECC forward primer 5= GCCATATGATGCCTACTTTACCCAAGGCC 3= (Nde1 site
underlined) and ECC reverse primer 5= GCGGATCCCTACAATTTTCGGAAGTACTCGG 3= (BamH1 site under-
lined). The vectors obtained were used to transfect both BF and PF T. brucei parental lines.
Trypanosome growth and transfection. The cell lines used were T. brucei subsp. brucei BF S16 (58)
and PF cell line 449 (59). The BF parasites were cultured at 37°C and 5% CO2 in HMI-9 medium containing
10% (vol/vol) FBS. The PF trypanosomes were cultured at 28°C in SDM-79 medium supplemented with
10% (vol/vol) FBS and 7.5 g·ml1 hemin. To generate LAP-A dKO and knockdown (RNAi) parasite cells
lines, as well as LAP-A and LAP-A-myc overexpression lines, parental BF and PF cells were transfected by
electroporation with 10 g of the respective targeting vectors as previously described (58). Recombi-
nants were selected in the presence of the corresponding drug used as a selectable marker. LAP-A-dKO
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and LAP-A-OE lines were also grown in leucine-free minimal medium (produced in our laboratory)
supplemented with 10% (vol/vol) dialyzed FBS and 7.5 g·ml1 hemin.
Three-dimensional immunofluorescence studies. Immunoﬂuorescence studies were performed as
previously described (60). Brieﬂy, for each sample 10  106 parasites were harvested by centrifugation,
resuspended in 1 ml of PBS containing MitoTracker Red (Invitrogen), and incubated in the dark at culture
temperature for 15 min. After one wash with 1 ml of PBS, cells were resuspended in 4% paraformalde-
hyde and wash solution (PBS plus 0.2% [vol/vol] Tween 20) and ﬁxed on a poly-L-lysine-coated glass slide.
The ﬁxed cells were washed twice and permeabilized with a solution of PBS, 1% Blocking Reagent
(Roche), and 1% IGEPAL (Sigma). The immunoﬂuorescence assay was performed with anti-TbLAP-A
primary polyclonal antibody (afﬁnity puriﬁed, diluted 1:500 for overexpressing cells and 1:100 for all
others) or anti-c-Myc monoclonal antibody (Sigma, 1:100) and ﬂuorescein isothiocyanate-conjugated
anti-rabbit secondary antibody (Sigma, 1:40), Alexa Fluor 488-conjugated anti-rabbit antibody (Sigma,
1:100), or Alexa Fluor 488-conjugated anti-mouse antibody (Sigma, 1:40). The slides were ﬁnally stained
and mounted with Vectashield-DAPI (Vector Laboratories, Inc.). Vertical stacks of 15 to 20 slices (0.2-m
steps) were captured with either an Olympus wide-ﬁeld microscope and Cell R IX81software or a Leica
SP5 confocal microscope. Images were deconvolved and pseudocolored with the Huygens Essential
software (version 3.3; Scientiﬁc Volume Imaging) and Fiji software (version 1.5e; ImageJ) (61), respec-
tively. Colocalization analysis (Pearson’s and Manders’ coefﬁcients) was performed by with the JACoP
plugin (62) in ImageJ. For nutritional stress studies, 25  106 parasites were washed twice in 1 PBS and
incubated for 60, 120, or 180 min in 1 PBS. After starvation treatment, immunoﬂuorescence assays were
performed as described above.
In vivo studies. Three groups of four female C57BL/6J mice (each around 8 weeks old) were used to
test TbLAP-A-RNAi cell line infectivity in vivo. One group was infected with the parental BF line, while the
two remaining groups were infected with the TbLAP-A-RNAi line. Each mouse was injected intraperito-
neally with 1,000 monomorphic parasites from a logarithmic culture. Drinking water containing doxy-
cycline (1 mg·ml1) was given to one of the groups infected with the TbLAP-A-RNAi line to induce protein
knockdown, while normal water was given to the other groups. Mouse survival was monitored for
1 week. The animal research described in this report complied with Spanish (Ley 32/2007) and European
Union (2010/63/UE) legislation. The protocols used were approved by the Animal Care Committee of the
Instituto de Parasitología y Biomedicina “López-Neyra,” CSIC (protocol CEEA/2014/DGP/1).
Accession number(s). Newly reported structures have been deposited in the PDB under accession
no. 5NSK, 5NSM, 5NSQ, 5NTD, and 5NTH.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00226-17.
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